AR037145A1 - Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias - Google Patents
Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatoriasInfo
- Publication number
- AR037145A1 AR037145A1 ARP020103548A ARP020103548A AR037145A1 AR 037145 A1 AR037145 A1 AR 037145A1 AR P020103548 A ARP020103548 A AR P020103548A AR P020103548 A ARP020103548 A AR P020103548A AR 037145 A1 AR037145 A1 AR 037145A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos, sus formas enantioméricas y diastereoméricas y sales farmacéuticamente aceptables, que tienen la fórmula (1), donde: R es -O[CH2]kR3 o -NR4aR4b; R3 es alquilo C1-4 sustituido o no sustituido, hidrocarbilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo o alquilenarilo sustituido o no sustituido, heteroarilo o alquilenheteroarilo sustituido o no sustituido; el índice k es 0 a 5; R4a y R4b independientemente cada uno son: hidrógeno; o -[C(R5aR5b)]mR6; cada R5a y R5b independientemente son hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-4 lineal, ramificado, o cíclico, y mezclas de éstos, R6 es hidrógeno, -OR7, -N(R7)2, -CO2R7, -CON(R7)2; alquilo C1-4 sustituido o no sustituido, heterocíclico, sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido R7 es hidrógeno, un catión soluble en agua, o alquilo C1-4; o arilo sustituido o no sustituido, el índice m es de 0 a 5; R1 es: arilo sustituido o no sustituido; o heteroarilo sustituido o no sustituido; cada unidad R2 es hidrógeno; -(CH2)jO(CH2)nR8; -(CH2)jNR9aR9b; -(CH2)jCO2R10; -(CH2)jOCO2R10, -(CH2)jCON(R10)2; -(CH2)jOCON(R10)2; dos unidades R2 pueden formar juntas una unidad de carbonilo; y mezclas de éstos; R8, R9a, R9b, y R10 independientemente cada uno son hidrógeno, alquilo C1-4 y mezclas de éstos; R9a y R9b pueden formar juntos un anillo carbocíclico o heterocíclico que comprende de 3 a 7 átomos; dos unidades R10 pueden formar juntos un anillo carbocíclico o heterocíclico que comprende de 3 a 7 átomos; j es un índice de 0 a 5; n es un índice de 0 a 5; Z es O, S, NR11, o NOR11; R11 es hidrógeno o alquilo C1-4. Composición farmacéutica que comprende dichos compuestos y uno o más excipientes farmacéuticamente aceptables. Uso para fabricar un medicamento para controlar la liberación extracelular de citoquinas inflamatorias, en casos de artritis reumatoide, osteoartritis, enfermedad inflamatoria del intestino, choque séptico y otras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32362501P | 2001-09-20 | 2001-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037145A1 true AR037145A1 (es) | 2004-10-27 |
Family
ID=23259997
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103549A AR037502A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de 6,7-dihidro-5h-pirazolo[1,2a]pirazol-1-ona espirociclico y su uso para fabricar una composicion farmaceutica |
| ARP020103548A AR037145A1 (es) | 2001-09-20 | 2002-09-20 | Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias |
| ARP020103550A AR037237A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de pirazolo de anillo fusionado, composicion que lo comprende y su uso para fabricar dicha composicion |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103549A AR037502A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de 6,7-dihidro-5h-pirazolo[1,2a]pirazol-1-ona espirociclico y su uso para fabricar una composicion farmaceutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103550A AR037237A1 (es) | 2001-09-20 | 2002-09-20 | Compuesto de pirazolo de anillo fusionado, composicion que lo comprende y su uso para fabricar dicha composicion |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6566357B1 (es) |
| EP (3) | EP1427732B1 (es) |
| JP (3) | JP2005504082A (es) |
| KR (4) | KR20040035837A (es) |
| CN (3) | CN1249066C (es) |
| AR (3) | AR037502A1 (es) |
| AT (3) | ATE287887T1 (es) |
| AU (2) | AU2002327690B2 (es) |
| BR (3) | BR0212716A (es) |
| CA (3) | CA2461073A1 (es) |
| CO (3) | CO5560589A2 (es) |
| CY (1) | CY1106398T1 (es) |
| CZ (3) | CZ2004361A3 (es) |
| DE (3) | DE60218704T2 (es) |
| DK (2) | DK1427732T3 (es) |
| EG (2) | EG24413A (es) |
| ES (3) | ES2282459T3 (es) |
| HK (2) | HK1071366A1 (es) |
| HU (3) | HUP0500752A2 (es) |
| IL (3) | IL160682A0 (es) |
| MA (3) | MA27066A1 (es) |
| MX (3) | MXPA04002570A (es) |
| MY (2) | MY129329A (es) |
| NO (2) | NO20041594L (es) |
| NZ (3) | NZ531123A (es) |
| PE (3) | PE20030446A1 (es) |
| PL (3) | PL370351A1 (es) |
| PT (3) | PT1427728E (es) |
| RU (3) | RU2278864C2 (es) |
| SA (1) | SA03230529B1 (es) |
| SK (3) | SK1502004A3 (es) |
| WO (3) | WO2003024970A1 (es) |
| ZA (3) | ZA200401260B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849627B2 (en) | 2001-09-20 | 2005-02-01 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7087615B2 (en) | 2001-09-20 | 2006-08-08 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7473695B2 (en) | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
| US6677337B2 (en) * | 2002-03-19 | 2004-01-13 | The Procter & Gamble Company | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines |
| CA2497007A1 (en) * | 2002-09-09 | 2004-03-18 | Amgen Inc. | 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations |
| WO2004087696A1 (de) * | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| US7482356B2 (en) * | 2003-11-10 | 2009-01-27 | The Procter & Gamble Company | Bicyclic pyrazolone cytokine inhibitors |
| MY144307A (en) * | 2006-04-18 | 2011-08-29 | Abbott Lab | Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| PL2432767T3 (pl) * | 2009-05-19 | 2013-11-29 | Dow Agrosciences Llc | Związki i sposoby zwalczania grzybów |
| CN107636366B (zh) | 2015-06-15 | 2021-03-12 | 卡明斯公司 | 燃烧室弹性装置 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| CN107033090B (zh) * | 2017-05-16 | 2019-05-07 | 无锡捷化医药科技有限公司 | 一种1,2,3,4-四氢噌啉的制备方法 |
| RU2721684C1 (ru) * | 2019-09-06 | 2020-05-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты |
| WO2023076133A1 (en) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054291A (es) * | 1963-02-26 | |||
| GB1124982A (en) * | 1965-02-09 | 1968-08-21 | Lepetit Spa | Diazabicyclo octanes and derivatives thereof |
| CH529153A (fr) | 1969-10-27 | 1972-10-15 | Lepetit Spa | Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones |
| US5358924A (en) * | 1991-03-21 | 1994-10-25 | Bayer Aktiengesellschaft | 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use |
| PT1481970E (pt) * | 1999-09-07 | 2006-07-31 | Syngenta Participations Ag | Novos herbicidas |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
-
2002
- 2002-09-18 US US10/246,499 patent/US6566357B1/en not_active Expired - Fee Related
- 2002-09-18 US US10/245,927 patent/US6821971B2/en not_active Expired - Fee Related
- 2002-09-20 WO PCT/US2002/030134 patent/WO2003024970A1/en active IP Right Grant
- 2002-09-20 PT PT02763693T patent/PT1427728E/pt unknown
- 2002-09-20 KR KR10-2004-7004046A patent/KR20040035837A/ko not_active Application Discontinuation
- 2002-09-20 BR BR0212716-4A patent/BR0212716A/pt not_active IP Right Cessation
- 2002-09-20 DK DK02799017T patent/DK1427732T3/da active
- 2002-09-20 CA CA002461073A patent/CA2461073A1/en not_active Abandoned
- 2002-09-20 PL PL02370351A patent/PL370351A1/xx not_active Application Discontinuation
- 2002-09-20 MX MXPA04002570A patent/MXPA04002570A/es active IP Right Grant
- 2002-09-20 CN CNB028183800A patent/CN1249066C/zh not_active Expired - Fee Related
- 2002-09-20 AR ARP020103549A patent/AR037502A1/es not_active Application Discontinuation
- 2002-09-20 WO PCT/US2002/030133 patent/WO2003024973A1/en not_active Application Discontinuation
- 2002-09-20 EP EP02799017A patent/EP1427732B1/en not_active Expired - Lifetime
- 2002-09-20 BR BR0212905-1A patent/BR0212905A/pt not_active IP Right Cessation
- 2002-09-20 MX MXPA04002569A patent/MXPA04002569A/es active IP Right Grant
- 2002-09-20 EP EP02763693A patent/EP1427728B1/en not_active Expired - Lifetime
- 2002-09-20 AR ARP020103548A patent/AR037145A1/es unknown
- 2002-09-20 SK SK150-2004A patent/SK1502004A3/sk unknown
- 2002-09-20 AU AU2002327690A patent/AU2002327690B2/en not_active Ceased
- 2002-09-20 KR KR1020047004043A patent/KR100656126B1/ko not_active IP Right Cessation
- 2002-09-20 SK SK148-2004A patent/SK1482004A3/sk unknown
- 2002-09-20 AT AT02763692T patent/ATE287887T1/de not_active IP Right Cessation
- 2002-09-20 CN CNB028182294A patent/CN1250551C/zh not_active Expired - Fee Related
- 2002-09-20 PT PT02763692T patent/PT1427727E/pt unknown
- 2002-09-20 IL IL16068202A patent/IL160682A0/xx unknown
- 2002-09-20 CN CNB028182286A patent/CN1257905C/zh not_active Expired - Fee Related
- 2002-09-20 ES ES02763693T patent/ES2282459T3/es not_active Expired - Lifetime
- 2002-09-20 MY MYPI20023518A patent/MY129329A/en unknown
- 2002-09-20 ES ES02799017T patent/ES2268154T3/es not_active Expired - Lifetime
- 2002-09-20 WO PCT/US2002/030135 patent/WO2003024971A1/en active IP Right Grant
- 2002-09-20 NZ NZ531123A patent/NZ531123A/en not_active IP Right Cessation
- 2002-09-20 MY MYPI20023502A patent/MY129069A/en unknown
- 2002-09-20 CZ CZ2004361A patent/CZ2004361A3/cs unknown
- 2002-09-20 RU RU2004111805/04A patent/RU2278864C2/ru active
- 2002-09-20 PT PT02799017T patent/PT1427732E/pt unknown
- 2002-09-20 PE PE2002000924A patent/PE20030446A1/es not_active Application Discontinuation
- 2002-09-20 DK DK02763693T patent/DK1427728T3/da active
- 2002-09-20 AR ARP020103550A patent/AR037237A1/es not_active Application Discontinuation
- 2002-09-20 HU HU0500752A patent/HUP0500752A2/hu unknown
- 2002-09-20 DE DE60218704T patent/DE60218704T2/de not_active Expired - Lifetime
- 2002-09-20 PE PE2002000925A patent/PE20030474A1/es not_active Application Discontinuation
- 2002-09-20 IL IL16074202A patent/IL160742A0/xx unknown
- 2002-09-20 PL PL02370415A patent/PL370415A1/xx not_active Application Discontinuation
- 2002-09-20 BR BR0212673-7A patent/BR0212673A/pt not_active IP Right Cessation
- 2002-09-20 NZ NZ531122A patent/NZ531122A/en unknown
- 2002-09-20 DE DE60202782T patent/DE60202782T2/de not_active Expired - Lifetime
- 2002-09-20 RU RU2004111803/04A patent/RU2299885C2/ru active
- 2002-09-20 NZ NZ531063A patent/NZ531063A/en not_active IP Right Cessation
- 2002-09-20 AT AT02799017T patent/ATE332901T1/de not_active IP Right Cessation
- 2002-09-20 ES ES02763692T patent/ES2237691T3/es not_active Expired - Lifetime
- 2002-09-20 MX MXPA04002574A patent/MXPA04002574A/es active IP Right Grant
- 2002-09-20 CZ CZ2004358A patent/CZ2004358A3/cs unknown
- 2002-09-20 HU HU0402500A patent/HUP0402500A3/hu unknown
- 2002-09-20 CA CA002461072A patent/CA2461072A1/en not_active Abandoned
- 2002-09-20 JP JP2003528818A patent/JP2005504082A/ja active Pending
- 2002-09-20 PE PE2002000923A patent/PE20030430A1/es not_active Application Discontinuation
- 2002-09-20 RU RU2004111806/04A patent/RU2272040C2/ru not_active IP Right Cessation
- 2002-09-20 PL PL02370362A patent/PL370362A1/xx not_active Application Discontinuation
- 2002-09-20 CA CA002461071A patent/CA2461071A1/en not_active Abandoned
- 2002-09-20 JP JP2003528820A patent/JP2005504083A/ja active Pending
- 2002-09-20 HU HU0402378A patent/HUP0402378A3/hu unknown
- 2002-09-20 EP EP02763692A patent/EP1427727B1/en not_active Expired - Lifetime
- 2002-09-20 DE DE60213108T patent/DE60213108T2/de not_active Expired - Fee Related
- 2002-09-20 CZ CZ2004345A patent/CZ2004345A3/cs unknown
- 2002-09-20 IL IL16074102A patent/IL160741A0/xx unknown
- 2002-09-20 KR KR1020067006983A patent/KR20060036125A/ko not_active Application Discontinuation
- 2002-09-20 AU AU2002334641A patent/AU2002334641B2/en not_active Expired - Fee Related
- 2002-09-20 AT AT02763693T patent/ATE356126T1/de not_active IP Right Cessation
- 2002-09-20 JP JP2003528817A patent/JP2005504081A/ja active Pending
- 2002-09-20 KR KR1020047004045A patent/KR100623879B1/ko not_active IP Right Cessation
- 2002-09-20 SK SK149-2004A patent/SK1492004A3/sk unknown
- 2002-09-21 EG EG2002091039A patent/EG24413A/xx active
- 2002-09-21 EG EG2002091037A patent/EG24363A/xx active
-
2003
- 2003-01-26 SA SA3230529A patent/SA03230529B1/ar unknown
-
2004
- 2004-02-17 ZA ZA200401260A patent/ZA200401260B/en unknown
- 2004-02-20 ZA ZA200401403A patent/ZA200401403B/en unknown
- 2004-02-20 ZA ZA200401402A patent/ZA200401402B/en unknown
- 2004-03-09 CO CO04021424A patent/CO5560589A2/es not_active Application Discontinuation
- 2004-03-09 CO CO04021425A patent/CO5560590A2/es not_active Application Discontinuation
- 2004-03-10 MA MA27569A patent/MA27066A1/fr unknown
- 2004-03-10 MA MA27568A patent/MA27065A1/fr unknown
- 2004-03-10 MA MA27567A patent/MA27064A1/fr unknown
- 2004-03-12 CO CO04023010A patent/CO5560579A2/es not_active Application Discontinuation
- 2004-04-19 NO NO20041594A patent/NO20041594L/no not_active Application Discontinuation
- 2004-04-20 NO NO20041605A patent/NO20041605L/no not_active Application Discontinuation
-
2005
- 2005-05-18 HK HK05104163A patent/HK1071366A1/xx not_active IP Right Cessation
- 2005-05-24 HK HK05104374A patent/HK1071565A1/xx not_active IP Right Cessation
-
2007
- 2007-03-20 CY CY20071100383T patent/CY1106398T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037145A1 (es) | Compuestos de 6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas, composicion farmaceutica que los comprende y uso para fabricar un medicamento para controlar citoquinas inflamatorias | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| DE69507476D1 (de) | Farnesyl-transferase-inhibitoren, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| UY27198A1 (es) | Nuevos compuestos antiinflamatorios de bencimidazol | |
| AR023823A1 (es) | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. | |
| BRPI0407387A (pt) | Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento | |
| AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| BR0315665A (pt) | Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento | |
| CL2004000778A1 (es) | Compuestos derivados de heterociclos de 5 miembros, inhibidores de la porteina tirosina fosfatasa 1b (ptp1b); composiciones farmaceuticas, utiles para tratar hipertension, obesidad, diabetes, hiperlipidemia. | |
| YU247190A (sh) | Heterociklični derivati, njihovo dobivanje i lekovi koji ih sadrže | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| BRPI0414570A (pt) | derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso | |
| DE69604060T2 (de) | Zwei polymerisierbare gruppen ein perfluoralkylenäthermakromer enthaltend | |
| HUP0401898A2 (hu) | 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik | |
| MEP56908A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor | |
| PT892794E (pt) | Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador | |
| AR051797A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR033659A1 (es) | El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contiene | |
| AR011094A1 (es) | Medicamento que contiene quinoxalinas en triple combinacion y el uso de quinoxalinas en triple combinacion con inhibidores de proteasas e inhibidoresde transcriptasa como medicamento para el tratamiento del sida y/o de infecciones por hiv | |
| CO5160292A1 (es) | Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales | |
| MX9400253A (es) | Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| CO5080752A1 (es) | INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB | |
| AR008543A1 (es) | Un compuesto de camptotecina, un medicamento, una composicion farmaceutica que lo comprende y el uso del compuesto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |